Telaprevir or boceprevir in HIV/HCV-1 co-infected patients in a real-life setting. Interim analysis (24 weeks). COINFECOVA-SEICV study.
Journal of the International AIDS Society, ISSN: 1758-2652, Vol: 17, Issue: 4 Suppl 3, Page: 19634
2014
- 11Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Captures11
- Readers11
- 11
Article Description
In general, HIV co-infected patients included in clinical trials evaluating the hepatitis C virus (HCV) therapy with telaprevir (TVR) or boceprevir (BOC) with advanced fibrosis, are scarce. We analyze data concerning the use of these drugs in a real-life clinical setting with patients affected by a more advanced degree of fibrosis in a Spanish cohort.
Bibliographic Details
http://dx.doi.org/10.7448/ias.17.4.19634; http://www.ncbi.nlm.nih.gov/pubmed/25394138; https://onlinelibrary.wiley.com/doi/10.7448/IAS.17.4.19634; http://doi.wiley.com/10.7448/IAS.17.4.19634; http://onlinelibrary.wiley.com/wol1/doi/10.7448/IAS.17.4.19634/fullpdf; https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.7448%2FIAS.17.4.19634; https://dx.doi.org/10.7448/ias.17.4.19634; https://onlinelibrary.wiley.com/doi/abs/10.7448/IAS.17.4.19634
Wiley
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know